Splenic infarction and bevacizumab.
Malka
David
D
Gustave Roussy Institute, Villejuif, France. malka@igr.fr
Van den Eynde
Marc
M
Boige
Valérie
V
Dromain
Clarisse
C
Ducreux
Michel
M
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D006801:Humans; D008297:Male; D008875:Middle Aged; D013159:Splenic Infarction / Q000209:etiology* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab